Real-world adjuvant treatment for high-risk early breast cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study enrolls adults with high-risk hormone receptor–positive, HER2‑negative early breast cancer who are receiving adjuvant abemaciclib, olaparib, or endocrine therapy as part of routine care. Participants complete questionnaires on quality of life and other patient-reported outcomes while investigators record tumor characteristics, genomic risk scores, treatments, and nodal status. Recruitment is planned for about two years and each patient will be followed for five years to capture long-term treatment patterns and patient experience. Collected data will be analyzed descriptively to describe real-world treatment distribution and quality-of-life outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients will be enrolled in the study if they meet all of the following inclusion criteria:
* Age ≥ 18 years
* Endocrine sensitivity defined as estrogen and or progesterone receptors expression as per local pathological standards
* Her 2 negativity determined as ASCO/CAP guidelines
* Patients receiving abemaciclib, olaparib and endocrine therapy, as per Italian drugs agency rules (AIFA)
* Written informed consent, signed and dated by the patients
* High-risk HR positive, Her2 negative early breast cancer patients with one of the following characteristics:

  * Anatomical stage IIA N0 with:

    * Grade 2 and evidence of high risk:
    * Ki-67 ≥ 20%
    * Oncotype DX Breast Recurrence Score ≥ 26 or High risk via genomic risk profiling
    * Grade 3
  * Anatomical stage IIB.
  * Pathological tumour involvement in ≥4 ipsilateral axillary lymph nodes.
  * Pathological tumour involvement in 1 to 3 ipsilateral axillary lymph node(s) (for patients who received neoadjuvant therapy also cytological tumour involvement at time of initial diagnosis is allowed) and meet at least 1 of the following criteria:

    * Grade 3 as defined by a combined score of at least 8 points per the modified Bloom-Richardson grading system (Elston and Ellis 1991),
    * Pathological primary invasive tumour size ≥5 cm (for patients who received neoadjuvant therapy primary tumour size ≥5 cm on breast imaging is allowed). Note: if tumour size is needed to meet eligibility criteria, patients with multifocal/multicentric tumours may be eligible based on the addition of diameters of the individual lesions.

BRCA mutated populations

Patients must be node positive and fulfil one of the following criteria:

* HR positive, HER2-negative patients must have had ≥4 pathologically confirmed positive lymph nodes
* patients who received prior neoadjuvant chemotherapy: must have had a CPS\&EG score of ≥3 based on pre-treatment clinical and post-treatment pathologic stage (CPS), estrogen receptor (ER) status and histologic grade

Exclusion Criteria:

* Patients unable to understand the reason for their participation in the study, lack of informed written consent,
* patients who do not meet the high risk criteria as specified in the inclusion criteria,
* patients suffering from other neoplasms for which they receive active treatment, or being diagnosed with other neoplasms (except for: Carcinoma in situ (CIS) of the cervix, CIS of the colon, basal cell and squamous cell carcinomas of the skin) in the five years before adjuvant treatment.

Where it's running

• Azienda Ospedaliero Universitaria Policlinico di Modena
  Modena, Modena, Italy Recruiting

Study contacts

• Study coordinator: Luca Moscetti, MD
• Email: moscetti.luca@aou.mo.it
• Phone: + 39.059.422.3244

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.